For the quarter ending 2025-09-30, AKBA had $29,141K increase in cash & cash equivalents over the period. $28,028K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 540 | 6,359 |
| Depreciation | 318 | 630 |
| Amortization of intangible asset | 0 | 0 |
| Bad debt expense | 426 | 959 |
| Change in fair value of warrant liability | -1,464 | 6,825 |
| Non-cash royalty revenue related to sale of future royalties | 462 | 863 |
| Non-cash interest expense | 4,619 | 12,437 |
| Non-cash operating lease expense | -1,150 | -2,231 |
| Non-cash loss on extinguishment of debt | 0 | 0 |
| Write-down of inventory | 530 | 115 |
| Change in excess inventory purchase commitments | 0 | 0 |
| Gain on the sale of property and equipment | 0 | 172 |
| Stock-based compensation expense | 3,221 | 4,863 |
| Accounts receivable | -6,160 | 39,400 |
| Inventory | -6,899 | 12,606 |
| Prepaid expenses and other current assets | -2,501 | -3,518 |
| Other long-term assets | -38 | -103 |
| Accounts payable | -8,828 | 1,491 |
| Accrued expense and other current liabilities | 15,824 | 18,778 |
| Operating lease liabilities | -1,364 | -2,647 |
| Deferred revenue | -1,651 | 5,532 |
| Other long-term liabilities | -352 | 605 |
| Net cash provided by (used in) operating activities | 28,105 | 8,758 |
| Purchases of equipment | 77 | 144 |
| Proceeds from the sale of property and equipment | 0 | 172 |
| Net cash used in investing activities | -77 | 28 |
| Proceeds from the issuance of debt | 0 | 10,000 |
| Payments of issuance costs related to blackrock credit agreement | 0 | 63 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 66,449 |
| Proceeds from issuance of stock under employee stock purchase plan | 152 | 78 |
| Proceeds from the exercise of stock options | 961 | 660 |
| Repayment of term debt | 0 | 462 |
| Net cash provided by financing activities | 1,113 | 76,662 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 29,141 | 85,448 |
| Cash and cash equivalents at beginning of period | 53,550 | - |
| Cash and cash equivalents at end of period | 168,139 | - |
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA)